Management
"HemoBioTech, Inc. is supported by strong management and a distinguished scientific and advisory team"
-- Arthur P. Bollon, Ph.D.
(Chief Executive Officer, President, and Board of Directors)
Arthur P. Bollon, Ph.D.
Chief Executive Officer, President, and Board of Directors
Robert Corner
Acting Chief Financial Officer
Mario Feola, M.D.
Chief Medical Officer
Jan Simoni, Ph.D., D.V.M.
Acting Vice President, Research and Development and Advisor
- Dr. Bollon brings 25 years experience in biotechnology as a scientist, executive and entrepreneur. He has been the Chairman, President and CEO of HemoBioTech since 2003.
- Founder, former Chairman & CEO of Wadley Biosciences Inc., a joint venture between Wadley Cancer Center and Phillips Petroleum.
- Founder, former Chairman & CEO of Cytoclonal Pharmaceutics – led an IPO in 1995 and closed licensing agreement with Bristol Meyers Squibb.
- Dr. Bollon holds a Ph.D. in molecular genetics from Rutgers University and was a Post Doctoral Fellow at Yale University.
- Former Chief Financial Officer of Bank One Management and Consulting Corporation.
- Former Audit Partner with Arthur Andersen & Co.
- Dr. Simoni is the co-inventor of HemoTech™ and a world-renowned blood substitute scientist.
- He is the Acting Vice President of R & D and Advisor at HemoBioTech and Associate Research Professor of Surgery and Internal Medicine at Texas Tech University Health Science Center.
- Co-author of over 100 publications, book chapters, and abstracts on human blood substitutes.
- Dr. Simoni holds a DVM and a Ph.D. from Wroclaw Agricultural University in Poland.
What sort of clinical research has been done on HemoTech™?
>>
- Dr. Feola is the co-inventor of HemoTech™ & a renowned blood substitute scientist
- He is the Chief Medical Officer of HemoBioTech. Co-authored over 100 scientific publications.
- Former Professor of Surgery at Texas Tech University Health Science Center & Chief of Surgery, VA Hospital.
- Dr. Feola holds an M.D. degree from University of Naples, Italy.